CEO Matthew Gline was paid $163,293,744 in fiscal year 2024, ↑ up 22020.9% from fiscal year 2023, the 99th percentile of its disclosed peer group (SEC filing 0001140361-25-027846 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$251,858,764 Mayukh Sukhatme total, FY2024 President and Chief Investment Officer — highest-paid officer; CEO Matthew Gline: $163,293,744 | 99th CEO (Matthew Gline) pay percentile vs peers | 518:1 CEO-to-median pay ratio | 60.91% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mayukh Sukhatme | $550,000 | $81,069,750 | $170,217,983 | — | — | — | $21,032 | $251,858,764 |
| President and Chief Investment Officer | ||||||||
| Matthew Gline | 725,000 | 4,978,875 | 157,577,851 | — | — | — | 12,018 | 163,293,744 |
| Chief Executive Officer | ||||||||
| Eric Venker | 600,208 | 6,038,175 | 2,203,200 | 2,933,103 | — | — | 32,736 | 11,807,422 |
| President and Immunovant CEO | ||||||||
| Rakhi Kumar | 370,156 | 1,650,328 | 412,382 | 1,862,828 | — | — | 398,244 | 4,693,938 |
| Former Chief Accounting Officer | ||||||||
| Richard Pulik | 437,750 | 1,113,674 | 410,061 | 2,163,910 | — | — | 1,755 | 4,127,151 |
| Chief Financial Officer | ||||||||
| Jennifer Humes | 41,897 | 281,450 | 1,231,437 | 826,878 | — | — | 1,293 | 2,382,956 |
| Chief Accounting Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Mayukh Sukhatme | $251,858,764 | $574,560 | $48,925,582 | ↑ +251,284,204 |
| Matthew Gline | 163,293,744 | 738,189 | 48,978,825 | ↑ +162,555,555 |
| Eric Venker | 11,807,422 | 632,420 | 48,487,966 | ↑ +11,175,002 |
| Rakhi Kumar | 4,693,938 | 4,331,159 | — | ↑ +362,779 |
| Richard Pulik | 4,127,151 | 5,149,434 | — | ↓ −1,022,283 |
| Jennifer Humes | 2,382,956 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Roivant Sciences Ltd.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ROIV reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Roivant Sciences Ltd. Peer Teardown Report
$251,858,764 Mayukh Sukhatme total, FY2024
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 5, 2026 · Source: 0001140361-25-027846 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for ROIV
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order ROIV
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses ROIV in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ROIV in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the Roivant Sciences Ltd. Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2024 total |
|---|---|---|
| Daniel Gold | Independent Director | $484,410 |
| Ilan Oren | Independent Director | $521,548 |
| James C. Momtazee | Independent Director | $473,844 |
| Keith Manchester | Independent Director | $476,660 |
| Meghan FitzGerald | Independent Director | $482,910 |
| Melissa Epperly | Independent Director | $489,410 |
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Richard Pulik | CFO | 2025-12-23 | D | 146,731 | $22 | $3,285,307 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2025-12-23 | A | 260,000 | 4 | 1,001,000 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2025-12-23 | A | 175,380 | 22 | 3,937,281 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2025-12-24 | D | 64,891 | 22 | 1,458,101 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-12-24 | D | 75,000 | 23 | 1,689,750 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-12-24 | A | 117,848 | 4 | 453,715 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2025-12-24 | D | 117,848 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2025-12-24 | D | 110,489 | 0 | 0 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-29 | D | 748,358 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-29 | D | 311,873 | 22 | 6,780,119 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-29 | D | 436,485 | 22 | 9,489,184 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-29 | A | 748,358 | 13 | 9,489,179 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-31 | D | 1,430,882 | 22 | 31,064,448 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-31 | D | 1,018,995 | 22 | 22,122,381 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-31 | D | 2,449,877 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2025-12-31 | A | 2,449,877 | 13 | 31,064,440 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-01-12 | D | 200,000 | 22 | 4,384,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-01-12 | A | 200,000 | 4 | 770,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-01-12 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-01-20 | D | 54 | 23 | 1,241 | Common | Form 4 ↗ |
| Ilan Oren | Director | 2026-01-20 | D | 124 | 23 | 2,850 | Common | Form 4 ↗ |
| James C. Momtazee | Director | 2026-01-20 | D | 122 | 23 | 2,804 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-01-20 | A | 815 | 0 | 0 | Common | Form 4 ↗ |
| Ilan Oren | Director | 2026-01-20 | A | 1,164 | 0 | 0 | Common | Form 4 ↗ |
| James C. Momtazee | Director | 2026-01-20 | A | 609 | 0 | 0 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-02-09 | D | 651,558 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-02-09 | D | 312,117 | 26 | 8,261,737 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-02-09 | A | 651,558 | 13 | 8,261,755 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-02-09 | D | 339,441 | 26 | 8,985,003 | Common | Form 4 ↗ |
| QVT Financial LP | — | 2026-02-11 | D | 425,000 | 27 | 11,334,750 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2026-02-11 | D | 425,000 | 27 | 11,334,750 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2026-02-11 | D | 425,000 | 27 | 11,334,750 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2026-02-12 | D | 275,000 | 27 | 7,359,000 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2026-02-12 | D | 150,000 | 27 | 4,008,000 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2026-02-12 | D | 275,000 | 27 | 7,359,000 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2026-02-12 | D | 150,000 | 27 | 4,008,000 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2026-02-12 | D | 275,000 | 27 | 7,359,000 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2026-02-12 | D | 150,000 | 27 | 4,008,000 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2026-02-13 | D | 225,000 | 27 | 5,962,500 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2026-02-13 | D | 150,784 | 26 | 3,994,268 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2026-02-13 | D | 225,000 | 27 | 5,962,500 | Common, indirect | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-02-13 | D | 200,000 | 26 | 5,298,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-02-13 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-02-13 | A | 200,000 | 4 | 770,000 | Common | Form 4 ↗ |
| QVT Financial LP | — | 2026-02-13 | D | 150,784 | 26 | 3,994,268 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2026-02-13 | D | 225,000 | 27 | 5,962,500 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2026-02-13 | D | 150,784 | 26 | 3,994,268 | Common, indirect | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2026-02-19 | D | 1,400,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2026-02-19 | D | 1,400,000 | 27 | 38,388,000 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2026-02-19 | A | 1,400,000 | 4 | 5,390,000 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2026-02-20 | D | 1,012,610 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2026-02-20 | D | 1,012,610 | 27 | 27,492,362 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2026-02-20 | A | 1,012,610 | 4 | 3,898,549 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2026-02-20 | D | 1,000 | 27 | 27,150 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-02-20 | D | 7,051 | 27 | 191,435 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2026-02-23 | A | 587,390 | 4 | 2,261,452 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2026-02-23 | D | 587,390 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2026-02-23 | D | 587,390 | 28 | 16,159,099 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-03-16 | D | 41,861 | 29 | 1,200,573 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-03-17 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-03-17 | D | 200,000 | 28 | 5,648,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-03-17 | A | 200,000 | 4 | 770,000 | Common | Form 4 ↗ |
| Jennifer Humes | Chief Accounting Officer | 2026-03-20 | D | 14,526 | 28 | 402,370 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2026-03-20 | D | 1,546 | 28 | 42,824 | Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-03-26 | D | 70,000 | 27 | 1,921,500 | Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-03-26 | D | 70,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-03-26 | A | 70,000 | 9 | 616,000 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2026-03-30 | D | 2,178,150 | 12 | 25,048,725 | Derivative, Class A Common | Form 4 ↗ |
| Matthew Gline | Director | 2026-03-30 | D | 53,826 | 26 | 1,421,545 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-03-30 | D | 29,809 | 26 | 787,256 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2026-03-30 | A | 97,319 | — | — | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-03-30 | D | 1,306,889 | 12 | 15,029,224 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-03-30 | A | 58,391 | — | — | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-03-31 | D | 187,512 | 28 | 5,194,082 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2026-03-31 | D | 304,684 | 28 | 8,439,747 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2026-03-31 | D | 160,035 | 28 | 4,432,970 | Common | Form 4 ↗ |
| Jennifer Humes | Chief Accounting Officer | 2026-04-08 | D | 13,538 | 28 | 384,073 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2026-04-16 | D | 289,774 | 29 | 8,449,810 | Common | Form 4 ↗ |
| Ilan Oren | Director | 2026-04-17 | D | 95 | 30 | 2,834 | Common | Form 4 ↗ |
| James C. Momtazee | Director | 2026-04-17 | A | 469 | 0 | 0 | Common | Form 4 ↗ |
| James C. Momtazee | Director | 2026-04-17 | D | 94 | 30 | 2,804 | Common | Form 4 ↗ |
| Ilan Oren | Director | 2026-04-17 | A | 896 | 0 | 0 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-04-17 | A | 670 | 0 | 0 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2026-04-20 | A | 84,026 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jennifer Humes | Chief Accounting Officer | 2026-04-20 | A | 27,157 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-04-20 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-04-20 | D | 200,000 | 30 | 5,918,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-04-20 | A | 200,000 | 4 | 770,000 | Common | Form 4 ↗ |
| Jennifer Humes | Chief Accounting Officer | 2026-04-20 | A | 29,173 | 0 | 0 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2026-04-20 | A | 60,644 | 0 | 0 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-05-20 | D | 34,483 | 32 | 1,117,594 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2026-05-20 | D | 18,962 | 32 | 614,558 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-05-22 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-05-22 | D | 200,000 | 30 | 6,054,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-05-22 | A | 200,000 | 4 | 770,000 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2026-06-20 | D | 2,129 | 31 | 66,914 | Common | Form 4 ↗ |
| Jennifer Humes | Chief Accounting Officer | 2026-06-20 | D | 3,582 | 31 | 112,582 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-06-24 | D | 46,234 | 34 | 1,549,301 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-06-24 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-06-24 | D | 153,766 | 33 | 5,081,966 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-06-24 | A | 200,000 | 4 | 770,000 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-06-25 | A | 500,000 | 4 | 1,925,000 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-06-25 | D | 500,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-06-25 | D | 500,000 | 34 | 17,065,000 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-06-26 | D | 500,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel Gold | Director | 2026-06-26 | D | 300,783 | 34 | 10,202,559 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2026-06-26 | D | 325,000 | 34 | 11,072,750 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2026-06-26 | D | 300,783 | 34 | 10,202,559 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2026-06-26 | D | 300,783 | 34 | 10,202,559 | Common, indirect | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-06-26 | D | 500,000 | 34 | 17,040,000 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-06-26 | A | 500,000 | 4 | 1,925,000 | Common | Form 4 ↗ |
| Daniel Gold | Director | 2026-06-26 | D | 325,000 | 34 | 11,072,750 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2026-06-26 | D | 325,000 | 34 | 11,072,750 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2026-06-29 | D | 600,000 | 35 | 20,754,000 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2026-06-29 | D | 200,000 | 34 | 6,888,000 | Common, indirect | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-06-29 | D | 17,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-06-29 | D | 2,748 | 35 | 95,383 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-06-29 | D | 15,002 | 34 | 514,869 | Common | Form 4 ↗ |
| Daniel Gold | Director | 2026-06-29 | D | 600,000 | 35 | 20,754,000 | Common, indirect | Form 4 ↗ |
| Daniel Gold | Director | 2026-06-29 | D | 200,000 | 34 | 6,888,000 | Common, indirect | Form 4 ↗ |
| QVT Financial LP | — | 2026-06-29 | D | 200,000 | 34 | 6,888,000 | Common, indirect | Form 4 ↗ |
| Keith Manchester | Director | 2026-06-29 | D | 600,000 | 35 | 20,754,000 | Common, indirect | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-06-29 | A | 17,750 | 4 | 79,165 | Common | Form 4 ↗ |
| QVT Financial LP | — | 2026-06-30 | D | 12,380 | 35 | 436,766 | Common, indirect | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-06-30 | A | 10,000 | 9 | 88,000 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2026-06-30 | D | 76,171 | 35 | 2,695,692 | Common | Form 4 ↗ |
| Keith Manchester | Director | 2026-06-30 | D | 12,380 | 35 | 436,766 | Common, indirect | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-06-30 | D | 46,878 | 35 | 1,659,012 | Common | Form 4 ↗ |
| Keith Manchester | Director | 2026-06-30 | D | 200,000 | 35 | 7,090,000 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2026-06-30 | D | 40,310 | 35 | 1,426,571 | Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-06-30 | D | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-06-30 | D | 10,000 | 35 | 349,000 | Common | Form 4 ↗ |
| Daniel Gold | Director | 2026-06-30 | D | 12,380 | 35 | 436,766 | Common, indirect | Form 4 ↗ |
| Ilan Oren | Director | 2026-07-17 | A | 775 | 0 | 0 | Common | Form 4 ↗ |
| James C. Momtazee | Director | 2026-07-17 | A | 405 | 0 | 0 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-07-17 | A | 543 | 0 | 0 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-07-27 | A | 200,000 | 4 | 770,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-07-27 | D | 200,000 | 35 | 6,990,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-07-27 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-14 | D | 243,177 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-14 | A | 243,177 | 4 | 936,231 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-14 | D | 243,177 | 36 | 8,810,303 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-17 | D | 284,707 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-17 | D | 284,707 | 36 | 10,320,629 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-17 | A | 284,707 | 4 | 1,096,122 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-18 | D | 31,801 | 37 | 1,182,361 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-18 | D | 136,942 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-18 | D | 105,141 | 37 | 3,847,109 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-18 | A | 31,801 | 4 | 122,434 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-18 | A | 105,141 | 4 | 404,793 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-19 | A | 172,899 | 4 | 665,661 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-19 | D | 172,899 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-19 | D | 172,899 | 37 | 6,426,656 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-08-20 | D | 13,909 | 37 | 512,408 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-20 | D | 17,519 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-20 | D | 17,519 | 37 | 653,459 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-20 | A | 17,519 | 4 | 67,448 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-21 | D | 144,756 | 36 | 5,280,699 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-21 | D | 144,756 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-08-21 | A | 144,756 | 4 | 557,311 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-08-28 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-08-28 | D | 166,182 | 36 | 5,921,065 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-08-28 | A | 200,000 | 4 | 770,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-08-28 | D | 33,818 | 36 | 1,232,328 | Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-09-08 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-09-08 | A | 20,000 | 9 | 176,000 | Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-09-08 | D | 20,000 | 40 | 798,000 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-09-10 | D | 2,179 | 41 | 89,208 | Common | Form 4 ↗ |
| James C. Momtazee | Director | 2026-09-10 | D | 2,905 | 41 | 118,931 | Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-09-10 | D | 1,743 | 41 | 71,358 | Common | Form 4 ↗ |
| Daniel Gold | Director | 2026-09-10 | D | 5,133 | 41 | 210,145 | Common | Form 4 ↗ |
| Ilan Oren | Director | 2026-09-10 | D | 2,378 | 41 | 97,355 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-09-15 | D | 4,338 | 40 | 172,002 | Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-09-15 | D | 400 | 40 | 16,180 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-09-15 | D | 600 | 40 | 24,228 | Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-09-15 | D | 4,712 | 40 | 186,972 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-09-16 | A | 5,054 | 0 | 0 | Common | Form 4 ↗ |
| James C. Momtazee | Director | 2026-09-16 | A | 10,531 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James C. Momtazee | Director | 2026-09-16 | A | 5,054 | 0 | 0 | Common | Form 4 ↗ |
| Ilan Oren | Director | 2026-09-16 | A | 5,054 | 0 | 0 | Common | Form 4 ↗ |
| Daniel Gold | Director | 2026-09-16 | A | 10,531 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel Gold | Director | 2026-09-16 | A | 5,054 | 0 | 0 | Common | Form 4 ↗ |
| Keith Manchester | Director | 2026-09-16 | A | 10,531 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Keith Manchester | Director | 2026-09-16 | A | 5,054 | 0 | 0 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-09-16 | A | 10,531 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ilan Oren | Director | 2026-09-16 | A | 10,531 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-09-16 | A | 10,531 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Meghan FitzGerald | Director | 2026-09-16 | A | 5,054 | 0 | 0 | Common | Form 4 ↗ |
| Richard Pulik | CFO | 2026-09-20 | D | 2,129 | 40 | 84,670 | Common | Form 4 ↗ |
| Jennifer Humes | Chief Accounting Officer | 2026-09-20 | D | 3,880 | 40 | 154,308 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-09-30 | D | 200,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-09-30 | D | 200,000 | 37 | 7,324,000 | Common | Form 4 ↗ |
| Eric Venker | President & Immunovant CEO | 2026-09-30 | A | 200,000 | 4 | 770,000 | Common | Form 4 ↗ |
| Mayukh Sukhatme | Director | 2026-09-30 | D | 46,879 | 37 | 1,714,365 | Common | Form 4 ↗ |
| Matthew Gline | Director | 2026-09-30 | D | 76,171 | 37 | 2,785,573 | Common | Form 4 ↗ |
| Frank Torti | President and Vant Chair | 2026-09-30 | A | 40,309 | 37 | 1,474,100 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-10-01 | D | 17,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-10-01 | D | 900 | 37 | 32,913 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-10-01 | D | 16,850 | 36 | 607,948 | Common | Form 4 ↗ |
| Epperly Melissa B, | Director | 2026-10-01 | A | 17,750 | 4 | 79,165 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Mayukh Sukhatme | RSU | 2024-07-26 | — | — | 1,836,547 | — | $19,834,708 |
| Jennifer Humes | RSU | 2025-03-20 | — | — | 112,255 | — | 1,231,437 |
| Rakhi Kumar | OPTION | 2024-04-22 | — | — | 230,548 | — | 1,862,828 |
| Richard Pulik | OPTION | 2024-04-22 | — | — | 302,594 | — | 2,163,910 |
| Jennifer Humes | OPTION | 2025-03-20 | — | — | 115,108 | — | 826,878 |
| Eric Venker | OPTION | 2024-07-26 | — | — | 409,000 | — | 2,933,103 |
| Rakhi Kumar | RSU | 2024-04-22 | — | — | 38,685 | — | 412,382 |
| Richard Pulik | RSU | 2024-04-22 | — | — | 38,685 | — | 410,061 |
| Matthew Gline | RSU | 2024-07-26 | — | — | 2,754,821 | — | 29,752,067 |
| Eric Venker | RSU | 2024-07-26 | — | — | 204,000 | — | 2,203,200 |
| Matthew Gline | PSU | 2024-07-26 | 2,125,595 | — | — | 14,450,000 | 127,825,784 |
| Mayukh Sukhatme | PSU | 2024-07-26 | 2,500,700 | — | — | 17,000,000 | 150,383,275 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Mayukh Sukhatme | $19,834,708 | $150,383,275 | $0 | 88.3% |
| Jennifer Humes | 1,231,437 | 0 | 826,878 | 0.0% |
| Rakhi Kumar | 412,382 | 0 | 1,862,828 | 0.0% |
| Richard Pulik | 410,061 | 0 | 2,163,910 | 0.0% |
| Eric Venker | 2,203,200 | 0 | 2,933,103 | 0.0% |
| Matthew Gline | 29,752,067 | 127,825,784 | 0 | 81.1% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Rakhi Kumar | Option | 230,548 | 10.6 | — |
| Mayukh Sukhatme | Option | 82,065 | 10 | — |
| Eric Venker | Option | 58,616 | 10 | — |
| Matthew Gline | Option | 46,894 | 10 | — |
| Eric Venker | Option | 23,447 | 10 | — |
| Richard Pulik | Option | 39,177 | 6 | — |
| Mayukh Sukhatme | RSU | 1,836,547 | — | 18,530,759 |
| Jennifer Humes | Option | 115,108 | 10.97 | — |
| Eric Venker | Option | 4,475,029 | 3.85 | — |
| Matthew Gline | PSU | 2,125,595 | — | 21,447,254 |
| Eric Venker | RSU | 39,584 | — | 399,403 |
| Matthew Gline | Option | 4,475,029 | 3.85 | — |
| Rakhi Kumar | RSU | 3,750 | — | 37,838 |
| Matthew Gline | Option | 58,616 | 10 | — |
| Matthew Gline | RSU | 2,754,821 | — | 27,796,144 |
| Mayukh Sukhatme | PSU | 2,500,700 | — | 25,232,063 |
| Richard Pulik | RSU | 27,502 | — | 277,495 |
| Eric Venker | Option | 409,000 | 10.8 | — |
| Rakhi Kumar | Option | 3,566 | 10 | — |
| Richard Pulik | Option | 302,594 | 10.6 | — |
| Rakhi Kumar | Option | 149,171 | 8.8 | — |
| Eric Venker | RSU | 204,000 | — | 2,058,360 |
| Matthew Gline | RSU | 39,584 | — | 399,403 |
| Rakhi Kumar | Option | 270,833 | 3.85 | — |
| Richard Pulik | RSU | 38,685 | — | 390,332 |
| Richard Pulik | RSU | 33,352 | — | 336,522 |
| Richard Pulik | Option | 270,833 | 3.85 | — |
| Rakhi Kumar | RSU | 38,685 | — | 390,332 |
| Rakhi Kumar | RSU | 33,352 | — | 336,522 |
| Jennifer Humes | RSU | 112,255 | — | 1,132,653 |
| Richard Pulik | Option | 199,737 | 8.8 | — |
| Mayukh Sukhatme | Option | 1,097,325 | 10.96 | — |
| Mayukh Sukhatme | Option | 4,475,029 | 3.85 | — |
Our executive compensation program is designed to advance those objectives through a pay for performance philosophy and the alignment of the long-term interests of our NEOs with those of the Company's shareholders.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-09-10 | 316,651,402 | 203,244,184 | 64,550,276 | 60.91% | Passed |
| 2024 | 2024-09-10 | 540,184,951 | 64,461,892 | 587,930 | 89.34% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-09-10 | 60.91%a |
| 2024 | 2024-09-10 | 89.34%b |
a. Approved under the standard stated in the filing — “Abstentions, where applicable, are not considered to be votes cast and therefore will have no effect on the outcome of the vote for any such proposals as long as a quorum exists.”.
b. Approved under the standard stated in the filing — “Abstentions, where applicable, are not considered to be votes cast and therefore will have no effect on the outcome of the vote for any such proposals as long as a quorum exists proxy materials, or contact your broker, bank or other agent to request a proxy form.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 518 : 1 |
|---|---|
| CEO total compensation | $163,293,744 |
| Median employee compensation | $315,444 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Ilan OrenIndependent · Compensation · Nominating/Governance (Chair) | $107,137 | $199,989 | $214,421 | $0 | $0 | $521,548 |
| Melissa EpperlyIndependent · Audit (Chair) | 75,000 | 199,989 | 214,421 | 0 | — | 489,410 |
| Daniel GoldIndependent · Compensation (Chair) | 70,000 | 199,989 | 214,421 | 0 | — | 484,410 |
| Meghan FitzGeraldIndependent · Audit · Nominating/Governance | 68,500 | 199,989 | 214,421 | 0 | — | 482,910 |
| Keith ManchesterIndependent · Audit | 62,250 | 199,989 | 214,421 | 0 | — | 476,660 |
| James C. MomtazeeIndependent · Nominating/Governance | 59,434 | 199,989 | 214,421 | 0 | — | 473,844 |
| Matthew GlineEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Mayukh SukhatmeEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 12,000 |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $442,321 |
| Equity awards (grant-date value) | $1,199,934 |
| All other compensation | $0 |
| Total cost of the board | $1,642,255 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Roivant Sciences Ltd. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Roivant Sciences Ltd..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Roivant Sciences Ltd. | 2024 | Matthew Gline | $725,000 | $157,577,851 | — | — | $163,293,744 |
| 2 | Exelixis, Inc. | 2025 | Michael Morrissey | 1,306,040 | 30,539,552 | 0 | 1,382,591 | 33,239,183 |
| 3 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 4 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 5 | Jazz Pharmaceuticals, Inc. | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 6 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 7 | BridgeBio Pharma, Inc. | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 8 | Revolution Medicines, Inc. | 2025 | Mark Goldsmith | 812,500 | 3,968,076 | 8,995,114 | 889,700 | 14,672,390 |
| 9 | Vaxcyte, Inc. | 2025 | Grant Pickering | 800,000 | 4,300,159 | 8,714,048 | 630,000 | 14,458,937 |
| 10 | Blueprint Medicines Corporation | 2024 | Kathryn Haviland | 821,363 | 7,472,480 | 4,315,144 | 854,217 | 13,477,004 |
| 11 | Neurocrine Biosciences Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 12 | Ionis Pharmaceuticals, Inc. | 2025 | Brett Monia | 1,051,776 | 8,444,838 | 1,438,105 | 0 | 13,350,777 |
| 13 | Cerevel Therapeutics Holdings, Inc. | 2022 | N. Anthony Coles | 642,735 | 0 | 10,085,985 | 496,706 | 11,225,426 |
| 14 | Karuna Therapeutics, Inc. | 2022 | Steven Paul | 700,000 | 0 | 9,905,953 | 609,000 | 11,224,103 |
| 15 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 16 | Axsome Therapeutics, Inc. | 2025 | Herriot Tabuteau | 835,000 | 5,533,554 | 2,833,237 | 876,750 | 10,283,492 |
| 17 | Intra-Cellular Therapies, Inc. | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 18 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 19 | ACADIA Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 20 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 21 | CRISPR Therapeutics, Inc. | 2025 | Samarth Kulkarni | 768,622 | 3,474,900 | 2,768,862 | 659,093 | 7,678,477 |
| 22 | Arcutis Biotherapeutics, Inc. | 2025 | Todd Franklin Watanabe | 713,333 | 2,067,190 | 3,848,958 | 579,584 | 7,223,065 |
| 23 | ImmunoGen, Inc. | 2022 | Mark Enyedy | 759,490 | — | 4,137,596 | 515,213 | 5,422,421 |
| 24 | MoonLake Immunotherapeutics | 2025 | Jorge Santos da Silva | 762,386 | 4,000,021 | 0 | 0 | 4,943,209 |
| 25 | Denali Therapeutics Inc. | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| — | Ascendis Pharma, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Roivant Sciences Ltd. | 94.5% | not disclosed | No | Aon |
| ACADIA Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Arcutis Biotherapeutics, Inc. | 125% | not disclosed | No | Pay Governance LLC |
| Ascendis Pharma, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Axsome Therapeutics, Inc. | 150% | RSU 33 · Options 33 · PSU 33 | No | Frederic W. Cook & Co., Inc. |
| Blueprint Medicines Corporation | 130% | RSU 37 · Options 32 · PSU 31 | Yes — Relative Total Stockholder Return (rTSR) | Aon |
| BridgeBio Pharma, Inc. | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Cerevel Therapeutics Holdings, Inc. | 128.8% | Options 100 | not disclosed | Pay Governance LLC |
| CRISPR Therapeutics, Inc. | not disclosed | not disclosed | not disclosed | Alpine Rewards, LLC |
| Denali Therapeutics Inc. | 145% | not disclosed | not disclosed | Alpine Rewards |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| ImmunoGen, Inc. | not disclosed | not disclosed | not disclosed | Aon |
| Incyte Corporation | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Intra-Cellular Therapies, Inc. | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| Ionis Pharmaceuticals, Inc. | not disclosed | PRSU 40 · Option 30 · RSU 30 | Yes — Relative TSR | Aon |
| Jazz Pharmaceuticals, Inc. | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Karuna Therapeutics, Inc. | 145% | Option 100 | not disclosed | Aon |
| MoonLake Immunotherapeutics | not disclosed | not disclosed | not disclosed | Deloitte |
| Neurocrine Biosciences Inc. | 105% | Options 50 · PSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Revolution Medicines, Inc. | 146% | Options 70 · RSU 30 | not disclosed | Compensia |
| Sarepta Therapeutics, Inc. | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| United Therapeutics Corporation | 221% | PSO 50 · PSU 50 | No | Aon |
| Vaxcyte, Inc. | 105% | not disclosed | not disclosed | Pay Governance |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Mayukh Sukhatme | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Summary Compensation Table”. As printed: 251,858,764. Filing ↗machine: r7 · c24 · span 771923–771935 |
| 2 | Section 01, Matthew Gline | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Summary Compensation Table”. As printed: 163,293,744. Filing ↗machine: r2 · c24 · span 751211–751223 |
| 3 | Section 01, Eric Venker | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Summary Compensation Table”. As printed: 11,807,422. Filing ↗machine: r10 · c24 · span 784327–784338 |
| 4 | Section 01, Rakhi Kumar | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Summary Compensation Table”. As printed: 4,693,938. Filing ↗machine: r14 · c24 · span 800174–800184 |
| 5 | Section 01, Richard Pulik | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Summary Compensation Table”. As printed: 4,127,151. Filing ↗machine: r5 · c24 · span 763609–763619 |
| 6 | Section 01, Jennifer Humes | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Summary Compensation Table”. As printed: 2,382,956. Filing ↗machine: r13 · c24 · span 795986–795996 |
| 7 | Section 03, Mayukh Sukhatme RSU | DEF 14A | 1900-01-01 | 0001140361-25-027846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 874340–874350 |
| 8 | Section 03, Jennifer Humes RSU | DEF 14A | 1900-01-01 | 0001140361-25-027846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 9 | Section 03, Rakhi Kumar OPTION | DEF 14A | 1900-01-01 | 0001140361-25-027846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 10 | Section 03, Richard Pulik OPTION | DEF 14A | 1900-01-01 | 0001140361-25-027846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 11 | Section 03, Jennifer Humes OPTION | DEF 14A | 1900-01-01 | 0001140361-25-027846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 12 | Section 03, Eric Venker OPTION | DEF 14A | 1900-01-01 | 0001140361-25-027846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 13 | Section 03, Rakhi Kumar RSU | DEF 14A | 1900-01-01 | 0001140361-25-027846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 14 | Section 03, Richard Pulik RSU | DEF 14A | 1900-01-01 | 0001140361-25-027846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 15 | Section 03, Matthew Gline RSU | DEF 14A | 1900-01-01 | 0001140361-25-027846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 852094–852104 |
| 16 | Section 03, Eric Venker RSU | DEF 14A | 1900-01-01 | 0001140361-25-027846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗ |
| 17 | Section 03, Matthew Gline PSU | DEF 14A | 1900-01-01 | 0001140361-25-027846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 846486–846498 |
| 18 | Section 03, Mayukh Sukhatme PSU | DEF 14A | 1900-01-01 | 0001140361-25-027846 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 868732–868744 |
| 19 | Section 07, pay ratio | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “CEO Pay Ratio”. As printed: 518 : 1. Filing ↗ |
| 20 | Section 08, Ilan Oren | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 521,548. Filing ↗machine: t63 · r4 · c15 · span 252945–253128 |
| 21 | Section 08, Melissa Epperly | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 489,410. Filing ↗machine: t63 · r6 · c15 · span 258817–259000 |
| 22 | Section 08, Daniel Gold | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 484,410. Filing ↗machine: t63 · r2 · c15 · span 247117–247300 |
| 23 | Section 08, Meghan FitzGerald | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 482,910. Filing ↗machine: t63 · r7 · c15 · span 261396–261578 |
| 24 | Section 08, Keith Manchester | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 476,660. Filing ↗machine: t63 · r3 · c15 · span 249838–250021 |
| 25 | Section 08, James C. Momtazee | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 473,844. Filing ↗machine: t63 · r5 · c15 · span 255664–255847 |
| 26 | Section 08, Matthew Gline | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 27 | Section 08, Mayukh Sukhatme | DEF 14A | 2025-07-29 | 0001140361-25-027846 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 28 | Section 02, Richard Pulik 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046787 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Richard Pulik 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046787 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Frank Torti 2025-12-23 | Form 4 | 2025-12-29 | 0001140361-25-046788 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Frank Torti 2025-12-24 | Form 4 | 2025-12-29 | 0001140361-25-046788 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Eric Venker 2025-12-24 | Form 4 | 2025-12-29 | 0001140361-25-046786 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Eric Venker 2025-12-24 | Form 4 | 2025-12-29 | 0001140361-25-046786 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Eric Venker 2025-12-24 | Form 4 | 2025-12-29 | 0001140361-25-046786 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Frank Torti 2025-12-24 | Form 4 | 2025-12-29 | 0001140361-25-046788 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Mayukh Sukhatme 2025-12-29 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Mayukh Sukhatme 2025-12-29 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Mayukh Sukhatme 2025-12-29 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Mayukh Sukhatme 2025-12-29 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Mayukh Sukhatme 2025-12-31 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Mayukh Sukhatme 2025-12-31 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Mayukh Sukhatme 2025-12-31 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Mayukh Sukhatme 2025-12-31 | Form 4 | 2025-12-31 | 0001140361-25-047122 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Eric Venker 2026-01-12 | Form 4 | 2026-01-14 | 0001140361-26-001239 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Eric Venker 2026-01-12 | Form 4 | 2026-01-14 | 0001140361-26-001239 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Eric Venker 2026-01-12 | Form 4 | 2026-01-14 | 0001140361-26-001239 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Epperly Melissa B, 2026-01-20 | Form 4 | 2026-01-22 | 0001140361-26-002085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Ilan Oren 2026-01-20 | Form 4 | 2026-01-22 | 0001140361-26-002086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, James C. Momtazee 2026-01-20 | Form 4 | 2026-01-22 | 0001140361-26-002087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Epperly Melissa B, 2026-01-20 | Form 4 | 2026-01-22 | 0001140361-26-002085 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Ilan Oren 2026-01-20 | Form 4 | 2026-01-22 | 0001140361-26-002086 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, James C. Momtazee 2026-01-20 | Form 4 | 2026-01-22 | 0001140361-26-002087 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Mayukh Sukhatme 2026-02-09 | Form 4 | 2026-02-11 | 0001635088-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Mayukh Sukhatme 2026-02-09 | Form 4 | 2026-02-11 | 0001635088-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Mayukh Sukhatme 2026-02-09 | Form 4 | 2026-02-11 | 0001635088-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Mayukh Sukhatme 2026-02-09 | Form 4 | 2026-02-11 | 0001635088-26-000015 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, QVT Financial LP 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Daniel Gold 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052128 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Keith Manchester 2026-02-11 | Form 4 | 2026-02-13 | 0001193125-26-052130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Daniel Gold 2026-02-12 | Form 4 | 2026-02-13 | 0001193125-26-052128 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Daniel Gold 2026-02-12 | Form 4 | 2026-02-13 | 0001193125-26-052128 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Keith Manchester 2026-02-12 | Form 4 | 2026-02-13 | 0001193125-26-052130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Keith Manchester 2026-02-12 | Form 4 | 2026-02-13 | 0001193125-26-052130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, QVT Financial LP 2026-02-12 | Form 4 | 2026-02-13 | 0001193125-26-052106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, QVT Financial LP 2026-02-12 | Form 4 | 2026-02-13 | 0001193125-26-052106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, QVT Financial LP 2026-02-13 | Form 4 | 2026-02-13 | 0001193125-26-052106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Daniel Gold 2026-02-13 | Form 4 | 2026-02-13 | 0001193125-26-052128 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Keith Manchester 2026-02-13 | Form 4 | 2026-02-13 | 0001193125-26-052130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Eric Venker 2026-02-13 | Form 4 | 2026-02-18 | 0001635088-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Eric Venker 2026-02-13 | Form 4 | 2026-02-18 | 0001635088-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Eric Venker 2026-02-13 | Form 4 | 2026-02-18 | 0001635088-26-000017 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, QVT Financial LP 2026-02-13 | Form 4 | 2026-02-13 | 0001193125-26-052106 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Daniel Gold 2026-02-13 | Form 4 | 2026-02-13 | 0001193125-26-052128 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Keith Manchester 2026-02-13 | Form 4 | 2026-02-13 | 0001193125-26-052130 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Frank Torti 2026-02-19 | Form 4 | 2026-02-23 | 0001635088-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Frank Torti 2026-02-19 | Form 4 | 2026-02-23 | 0001635088-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Frank Torti 2026-02-19 | Form 4 | 2026-02-23 | 0001635088-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Frank Torti 2026-02-20 | Form 4 | 2026-02-23 | 0001635088-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Frank Torti 2026-02-20 | Form 4 | 2026-02-23 | 0001635088-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Frank Torti 2026-02-20 | Form 4 | 2026-02-23 | 0001635088-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Richard Pulik 2026-02-20 | Form 4 | 2026-02-24 | 0001635088-26-000023 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Eric Venker 2026-02-20 | Form 4 | 2026-02-24 | 0001635088-26-000022 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Frank Torti 2026-02-23 | Form 4 | 2026-02-23 | 0001635088-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Frank Torti 2026-02-23 | Form 4 | 2026-02-23 | 0001635088-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Frank Torti 2026-02-23 | Form 4 | 2026-02-23 | 0001635088-26-000019 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Epperly Melissa B, 2026-03-16 | Form 4 | 2026-03-18 | 0001807359-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Eric Venker 2026-03-17 | Form 4 | 2026-03-19 | 0001635088-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Eric Venker 2026-03-17 | Form 4 | 2026-03-19 | 0001635088-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Eric Venker 2026-03-17 | Form 4 | 2026-03-19 | 0001635088-26-000026 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Jennifer Humes 2026-03-20 | Form 4 | 2026-03-24 | 0001635088-26-000029 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Richard Pulik 2026-03-20 | Form 4 | 2026-03-24 | 0001635088-26-000030 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Meghan FitzGerald 2026-03-26 | Form 4 | 2026-03-30 | 0001140361-26-012063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Meghan FitzGerald 2026-03-26 | Form 4 | 2026-03-30 | 0001140361-26-012063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Meghan FitzGerald 2026-03-26 | Form 4 | 2026-03-30 | 0001140361-26-012063 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Matthew Gline 2026-03-30 | Form 4 | 2026-04-01 | 0001635088-26-000034 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Matthew Gline 2026-03-30 | Form 4 | 2026-04-01 | 0001635088-26-000034 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Mayukh Sukhatme 2026-03-30 | Form 4 | 2026-04-01 | 0001635088-26-000033 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Matthew Gline 2026-03-30 | Form 4 | 2026-04-01 | 0001635088-26-000034 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Mayukh Sukhatme 2026-03-30 | Form 4 | 2026-04-01 | 0001635088-26-000033 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Mayukh Sukhatme 2026-03-30 | Form 4 | 2026-04-01 | 0001635088-26-000033 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Mayukh Sukhatme 2026-03-31 | Form 4 | 2026-04-01 | 0001635088-26-000033 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Matthew Gline 2026-03-31 | Form 4 | 2026-04-01 | 0001635088-26-000034 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Frank Torti 2026-03-31 | Form 4 | 2026-04-02 | 0001635088-26-000036 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Jennifer Humes 2026-04-08 | Form 4 | 2026-04-10 | 0001140361-26-014301 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Matthew Gline 2026-04-16 | Form 4 | 2026-04-20 | 0001635088-26-000038 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Ilan Oren 2026-04-17 | Form 4 | 2026-04-21 | 0001140361-26-015985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, James C. Momtazee 2026-04-17 | Form 4 | 2026-04-21 | 0001209181-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, James C. Momtazee 2026-04-17 | Form 4 | 2026-04-21 | 0001209181-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Ilan Oren 2026-04-17 | Form 4 | 2026-04-21 | 0001140361-26-015985 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Epperly Melissa B, 2026-04-17 | Form 4 | 2026-04-21 | 0001807359-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Richard Pulik 2026-04-20 | Form 4 | 2026-04-22 | 0001635088-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Jennifer Humes 2026-04-20 | Form 4 | 2026-04-22 | 0001635088-26-000042 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Eric Venker 2026-04-20 | Form 4 | 2026-04-22 | 0001635088-26-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Eric Venker 2026-04-20 | Form 4 | 2026-04-22 | 0001635088-26-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Eric Venker 2026-04-20 | Form 4 | 2026-04-22 | 0001635088-26-000044 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Jennifer Humes 2026-04-20 | Form 4 | 2026-04-22 | 0001635088-26-000042 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Richard Pulik 2026-04-20 | Form 4 | 2026-04-22 | 0001635088-26-000043 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, Eric Venker 2026-05-20 | Form 4 | 2026-05-22 | 0001635088-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, Richard Pulik 2026-05-20 | Form 4 | 2026-05-22 | 0001635088-26-000064 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, Eric Venker 2026-05-22 | Form 4 | 2026-05-22 | 0001635088-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Eric Venker 2026-05-22 | Form 4 | 2026-05-22 | 0001635088-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Eric Venker 2026-05-22 | Form 4 | 2026-05-22 | 0001635088-26-000065 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Richard Pulik 2026-06-20 | Form 4 | 2026-06-23 | 0001635088-26-000069 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Jennifer Humes 2026-06-20 | Form 4 | 2026-06-23 | 0001635088-26-000067 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Eric Venker 2026-06-24 | Form 4 | 2026-06-26 | 0001635088-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Eric Venker 2026-06-24 | Form 4 | 2026-06-26 | 0001635088-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Eric Venker 2026-06-24 | Form 4 | 2026-06-26 | 0001635088-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Eric Venker 2026-06-24 | Form 4 | 2026-06-26 | 0001635088-26-000071 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Mayukh Sukhatme 2026-06-25 | Form 4 | 2026-06-29 | 0001635088-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Mayukh Sukhatme 2026-06-25 | Form 4 | 2026-06-29 | 0001635088-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Mayukh Sukhatme 2026-06-25 | Form 4 | 2026-06-29 | 0001635088-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Mayukh Sukhatme 2026-06-26 | Form 4 | 2026-06-29 | 0001635088-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Daniel Gold 2026-06-26 | Form 4 | 2026-06-30 | 0001193125-26-291163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, QVT Financial LP 2026-06-26 | Form 4 | 2026-06-30 | 0001193125-26-291139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, QVT Financial LP 2026-06-26 | Form 4 | 2026-06-30 | 0001193125-26-291139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Keith Manchester 2026-06-26 | Form 4 | 2026-06-30 | 0001193125-26-291172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Mayukh Sukhatme 2026-06-26 | Form 4 | 2026-06-29 | 0001635088-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Mayukh Sukhatme 2026-06-26 | Form 4 | 2026-06-29 | 0001635088-26-000073 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Daniel Gold 2026-06-26 | Form 4 | 2026-06-30 | 0001193125-26-291163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Keith Manchester 2026-06-26 | Form 4 | 2026-06-30 | 0001193125-26-291172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, QVT Financial LP 2026-06-29 | Form 4 | 2026-06-30 | 0001193125-26-291139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Keith Manchester 2026-06-29 | Form 4 | 2026-06-30 | 0001193125-26-291172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Epperly Melissa B, 2026-06-29 | Form 4 | 2026-07-01 | 0001807359-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Epperly Melissa B, 2026-06-29 | Form 4 | 2026-07-01 | 0001807359-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Epperly Melissa B, 2026-06-29 | Form 4 | 2026-07-01 | 0001807359-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Daniel Gold 2026-06-29 | Form 4 | 2026-06-30 | 0001193125-26-291163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Daniel Gold 2026-06-29 | Form 4 | 2026-06-30 | 0001193125-26-291163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, QVT Financial LP 2026-06-29 | Form 4 | 2026-06-30 | 0001193125-26-291139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Keith Manchester 2026-06-29 | Form 4 | 2026-06-30 | 0001193125-26-291172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Epperly Melissa B, 2026-06-29 | Form 4 | 2026-07-01 | 0001807359-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, QVT Financial LP 2026-06-30 | Form 4 | 2026-06-30 | 0001193125-26-291139 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Meghan FitzGerald 2026-06-30 | Form 4 | 2026-07-02 | 0001349297-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Matthew Gline 2026-06-30 | Form 4 | 2026-07-02 | 0001635088-26-000079 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Keith Manchester 2026-06-30 | Form 4 | 2026-06-30 | 0001193125-26-291172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Mayukh Sukhatme 2026-06-30 | Form 4 | 2026-07-02 | 0001635088-26-000075 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Keith Manchester 2026-06-30 | Form 4 | 2026-06-30 | 0001193125-26-291172 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Frank Torti 2026-06-30 | Form 4 | 2026-07-02 | 0001635088-26-000077 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Meghan FitzGerald 2026-06-30 | Form 4 | 2026-07-02 | 0001349297-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Meghan FitzGerald 2026-06-30 | Form 4 | 2026-07-02 | 0001349297-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, Daniel Gold 2026-06-30 | Form 4 | 2026-06-30 | 0001193125-26-291163 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, Ilan Oren 2026-07-17 | Form 4 | 2026-07-21 | 0001140361-26-029191 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, James C. Momtazee 2026-07-17 | Form 4 | 2026-07-21 | 0001140361-26-029193 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Epperly Melissa B, 2026-07-17 | Form 4 | 2026-07-21 | 0001140361-26-029192 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Eric Venker 2026-07-27 | Form 4 | 2026-07-29 | 0001140361-26-030107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Eric Venker 2026-07-27 | Form 4 | 2026-07-29 | 0001140361-26-030107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Eric Venker 2026-07-27 | Form 4 | 2026-07-29 | 0001140361-26-030107 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Mayukh Sukhatme 2026-08-14 | Form 4 | 2026-08-18 | 0001140361-26-033637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Mayukh Sukhatme 2026-08-14 | Form 4 | 2026-08-18 | 0001140361-26-033637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Mayukh Sukhatme 2026-08-14 | Form 4 | 2026-08-18 | 0001140361-26-033637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, Mayukh Sukhatme 2026-08-17 | Form 4 | 2026-08-18 | 0001140361-26-033637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, Mayukh Sukhatme 2026-08-17 | Form 4 | 2026-08-18 | 0001140361-26-033637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Mayukh Sukhatme 2026-08-17 | Form 4 | 2026-08-18 | 0001140361-26-033637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Mayukh Sukhatme 2026-08-18 | Form 4 | 2026-08-18 | 0001140361-26-033637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Mayukh Sukhatme 2026-08-18 | Form 4 | 2026-08-18 | 0001140361-26-033637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Mayukh Sukhatme 2026-08-18 | Form 4 | 2026-08-18 | 0001140361-26-033637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Mayukh Sukhatme 2026-08-18 | Form 4 | 2026-08-18 | 0001140361-26-033637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Mayukh Sukhatme 2026-08-18 | Form 4 | 2026-08-18 | 0001140361-26-033637 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Mayukh Sukhatme 2026-08-19 | Form 4 | 2026-08-21 | 0001140361-26-034066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 02, Mayukh Sukhatme 2026-08-19 | Form 4 | 2026-08-21 | 0001140361-26-034066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 180 | Section 02, Mayukh Sukhatme 2026-08-19 | Form 4 | 2026-08-21 | 0001140361-26-034066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 181 | Section 02, Eric Venker 2026-08-20 | Form 4 | 2026-08-24 | 0001140361-26-034238 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 182 | Section 02, Mayukh Sukhatme 2026-08-20 | Form 4 | 2026-08-21 | 0001140361-26-034066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 183 | Section 02, Mayukh Sukhatme 2026-08-20 | Form 4 | 2026-08-21 | 0001140361-26-034066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 184 | Section 02, Mayukh Sukhatme 2026-08-20 | Form 4 | 2026-08-21 | 0001140361-26-034066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 185 | Section 02, Mayukh Sukhatme 2026-08-21 | Form 4 | 2026-08-21 | 0001140361-26-034066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 186 | Section 02, Mayukh Sukhatme 2026-08-21 | Form 4 | 2026-08-21 | 0001140361-26-034066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 187 | Section 02, Mayukh Sukhatme 2026-08-21 | Form 4 | 2026-08-21 | 0001140361-26-034066 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 188 | Section 02, Eric Venker 2026-08-28 | Form 4 | 2026-09-01 | 0001140361-26-035375 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 189 | Section 02, Eric Venker 2026-08-28 | Form 4 | 2026-09-01 | 0001140361-26-035375 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 190 | Section 02, Eric Venker 2026-08-28 | Form 4 | 2026-09-01 | 0001140361-26-035375 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 191 | Section 02, Eric Venker 2026-08-28 | Form 4 | 2026-09-01 | 0001140361-26-035375 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 192 | Section 02, Meghan FitzGerald 2026-09-08 | Form 4 | 2026-09-10 | 0001140361-26-036246 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 193 | Section 02, Meghan FitzGerald 2026-09-08 | Form 4 | 2026-09-10 | 0001140361-26-036246 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 194 | Section 02, Meghan FitzGerald 2026-09-08 | Form 4 | 2026-09-10 | 0001140361-26-036246 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 195 | Section 02, Epperly Melissa B, 2026-09-10 | Form 4 | 2026-09-14 | 0001807359-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 196 | Section 02, James C. Momtazee 2026-09-10 | Form 4 | 2026-09-14 | 0001209181-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 197 | Section 02, Meghan FitzGerald 2026-09-10 | Form 4 | 2026-09-14 | 0001349297-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 198 | Section 02, Daniel Gold 2026-09-10 | Form 4 | 2026-09-14 | 0001140361-26-036535 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 199 | Section 02, Ilan Oren 2026-09-10 | Form 4 | 2026-09-14 | 0001635088-26-000092 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 200 | Section 02, Epperly Melissa B, 2026-09-15 | Form 4 | 2026-09-17 | 0001807359-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 201 | Section 02, Meghan FitzGerald 2026-09-15 | Form 4 | 2026-09-17 | 0001349297-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 202 | Section 02, Epperly Melissa B, 2026-09-15 | Form 4 | 2026-09-17 | 0001807359-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 203 | Section 02, Meghan FitzGerald 2026-09-15 | Form 4 | 2026-09-17 | 0001349297-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 204 | Section 02, Epperly Melissa B, 2026-09-16 | Form 4 | 2026-09-18 | 0001807359-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 205 | Section 02, James C. Momtazee 2026-09-16 | Form 4 | 2026-09-18 | 0001209181-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 206 | Section 02, James C. Momtazee 2026-09-16 | Form 4 | 2026-09-18 | 0001209181-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 207 | Section 02, Ilan Oren 2026-09-16 | Form 4 | 2026-09-18 | 0001635088-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 208 | Section 02, Daniel Gold 2026-09-16 | Form 4 | 2026-09-18 | 0001635088-26-000102 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 209 | Section 02, Daniel Gold 2026-09-16 | Form 4 | 2026-09-18 | 0001635088-26-000102 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 210 | Section 02, Keith Manchester 2026-09-16 | Form 4 | 2026-09-18 | 0001140361-26-037158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 211 | Section 02, Keith Manchester 2026-09-16 | Form 4 | 2026-09-18 | 0001140361-26-037158 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 212 | Section 02, Epperly Melissa B, 2026-09-16 | Form 4 | 2026-09-18 | 0001807359-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 213 | Section 02, Ilan Oren 2026-09-16 | Form 4 | 2026-09-18 | 0001635088-26-000099 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 214 | Section 02, Meghan FitzGerald 2026-09-16 | Form 4 | 2026-09-18 | 0001349297-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 215 | Section 02, Meghan FitzGerald 2026-09-16 | Form 4 | 2026-09-18 | 0001349297-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 216 | Section 02, Richard Pulik 2026-09-20 | Form 4 | 2026-09-22 | 0001635088-26-000104 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 217 | Section 02, Jennifer Humes 2026-09-20 | Form 4 | 2026-09-22 | 0001140361-26-037363 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 218 | Section 02, Eric Venker 2026-09-30 | Form 4 | 2026-10-02 | 0001635088-26-000108 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 219 | Section 02, Eric Venker 2026-09-30 | Form 4 | 2026-10-02 | 0001635088-26-000108 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 220 | Section 02, Eric Venker 2026-09-30 | Form 4 | 2026-10-02 | 0001635088-26-000108 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 221 | Section 02, Mayukh Sukhatme 2026-09-30 | Form 4 | 2026-10-02 | 0001635088-26-000109 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 222 | Section 02, Matthew Gline 2026-09-30 | Form 4 | 2026-10-02 | 0001140361-26-038475 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 223 | Section 02, Frank Torti 2026-09-30 | Form 4 | 2026-10-02 | 0001140361-26-038474 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 224 | Section 02, Epperly Melissa B, 2026-10-01 | Form 4 | 2026-10-05 | 0001807359-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 225 | Section 02, Epperly Melissa B, 2026-10-01 | Form 4 | 2026-10-05 | 0001807359-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 226 | Section 02, Epperly Melissa B, 2026-10-01 | Form 4 | 2026-10-05 | 0001807359-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 227 | Section 02, Epperly Melissa B, 2026-10-01 | Form 4 | 2026-10-05 | 0001807359-26-000018 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 228 | Section 06, 2025 vote | Form 8-K | 2025-09-11 | 0001140361-25-034711 | Item 5.07 · say-on-pay result. As reported: 60.91% (votes for as printed: 316,651,402). Filing ↗ |
| 229 | Section 06, 2024 vote | Form 8-K | 2024-09-16 | 0001140361-24-041188 | Item 5.07 · say-on-pay result. As reported: 89.34% (votes for as printed: 540,184,951). Filing ↗ |
| 230 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 231 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 232 | Section 09b board cost (computed) | Computed | — | — | Cash 442,321 + equity 1,199,934 + all other 0 = 1,642,255, summed across the director compensation table rows.machine: formula: Σ = 1,642,255 |
| 233 | Roivant Sciences Ltd. (subject), Section 10b CEO total | DEF 14A | 2025-07-29 | 0001140361-25-027846 | CEO total compensation as printed in Roivant Sciences Ltd.'s own proxy. As printed: 163,293,744. Filing ↗machine: r2 · c24 · span 751211–751223 |
| 234 | Exelixis, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000939767-26-000046 | CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. Filing ↗machine: r2 · c10 · span 2655516–2655526 |
| 235 | Incyte Corporation, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 236 | Halozyme Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 237 | Jazz Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-06-08 | 0001232524-26-000029 | CEO total compensation as printed in Jazz Pharmaceuticals, Inc.'s own proxy. As printed: 19,151,558. Filing ↗machine: r3 · c27 · span 1437369–1437379 |
| 238 | United Therapeutics Corporation, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001082554-26-000009 | CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. Filing ↗machine: span 1993726–1993736 |
| 239 | BridgeBio Pharma, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016723 | CEO total compensation as printed in BridgeBio Pharma, Inc.'s own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531 |
| 240 | Revolution Medicines, Inc., Section 10b CEO total | DEF 14A | 2026-04-27 | 0001193125-26-182453 | CEO total compensation as printed in Revolution Medicines, Inc.'s own proxy. As printed: 14,672,390. Filing ↗machine: r2 · c27 · span 382608–382618 |
| 241 | Vaxcyte, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001193125-26-173672 | CEO total compensation as printed in Vaxcyte, Inc.'s own proxy. As printed: 14,458,937. Filing ↗machine: r2 · c30 · span 561197–561207 |
| 242 | Blueprint Medicines Corporation, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001558370-25-005415 | CEO total compensation as printed in Blueprint Medicines Corporation's own proxy. As printed: 13,477,004. Filing ↗machine: span 1101152–1101162 |
| 243 | Neurocrine Biosciences Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0000914475-26-000015 | CEO total compensation as printed in Neurocrine Biosciences Inc.'s own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957 |
| 244 | Ionis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001140361-26-016388 | CEO total compensation as printed in Ionis Pharmaceuticals, Inc.'s own proxy. As printed: 13,350,777. Filing ↗ |
| 245 | Cerevel Therapeutics Holdings, Inc., Section 10b CEO total | DEF 14A | 2023-04-28 | 0000950170-23-015766 | CEO total compensation as printed in Cerevel Therapeutics Holdings, Inc.'s own proxy. As printed: 11,225,426. Filing ↗machine: t23 · r2 · c29 · span 1010006–1010016 |
| 246 | Karuna Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2023-04-27 | 0000950170-23-014979 | CEO total compensation as printed in Karuna Therapeutics, Inc.'s own proxy. As printed: 11,224,103. Filing ↗machine: r2 · c25 · span 856684–856694 |
| 247 | Apellis Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2025-04-23 | 0000950170-25-056966 | CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. Filing ↗machine: r2 · c25 · span 951555–951565 |
| 248 | Axsome Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177610 | CEO total compensation as printed in Axsome Therapeutics, Inc.'s own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246 |
| 249 | Intra-Cellular Therapies, Inc., Section 10b CEO total | DEF 14A | 2024-04-29 | 0001628280-24-018986 | CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. Filing ↗machine: r2 · c39 · span 440593–440603 |
| 250 | Amicus Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136 |
| 251 | ACADIA Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in ACADIA Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. Filing ↗ |
| 252 | Sarepta Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177247 | CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. Filing ↗machine: span 1454395–1454404 |
| 253 | CRISPR Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001193125-26-165158 | CEO total compensation as printed in CRISPR Therapeutics, Inc.'s own proxy. As printed: 7,678,477. Filing ↗machine: r2 · c25 · span 821649–821658 |
| 254 | Arcutis Biotherapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001787306-26-000028 | CEO total compensation as printed in Arcutis Biotherapeutics, Inc.'s own proxy. As printed: 7,223,065. Filing ↗machine: r2 · c42 · span 646815–646824 |
| 255 | ImmunoGen, Inc., Section 10b CEO total | DEF 14A | 2023-04-26 | 0001558370-23-006874 | CEO total compensation as printed in ImmunoGen, Inc.'s own proxy. As printed: 5,422,421. Filing ↗ |
| 256 | MoonLake Immunotherapeutics, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001140361-26-015916 | CEO total compensation as printed in MoonLake Immunotherapeutics's own proxy. As printed: 4,943,209. Filing ↗machine: t83 · r2 · c24 · span 431198–431207 |
| 257 | Denali Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001714899-26-000054 | CEO total compensation as printed in Denali Therapeutics Inc.'s own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614 |
| 258 | Section 10a, Jazz Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001232524-26-000029 | Jazz Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 259 | Section 10a, Amicus Therapeutics, Inc. reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 260 | Section 10a, MoonLake Immunotherapeutics reciprocity | DEF 14A | — | 0001140361-26-015916 | MoonLake Immunotherapeutics's most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 261 | Section 10a, Exelixis, Inc. reciprocity | DEF 14A | — | 0000939767-26-000046 | Exelixis, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 262 | Section 10a, Neurocrine Biosciences Inc. reciprocity | DEF 14A | — | 0000914475-26-000015 | Neurocrine Biosciences Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 263 | Section 10a, Revolution Medicines, Inc. reciprocity | DEF 14A | — | 0001193125-26-182453 | Revolution Medicines, Inc. names Roivant Sciences Ltd. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 264 | Section 10a, Sarepta Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177247 | Sarepta Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 265 | Section 10a, United Therapeutics Corporation reciprocity | DEF 14A | — | 0001082554-26-000009 | United Therapeutics Corporation's most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 266 | Section 10a, Ionis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001140361-26-016388 | Ionis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 267 | Section 10a, ACADIA Pharmaceuticals Inc. reciprocity | DEF 14A | — | 0001193125-26-174163 | ACADIA Pharmaceuticals Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 268 | Section 10a, CRISPR Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-165158 | CRISPR Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 269 | Section 10a, Denali Therapeutics Inc. reciprocity | DEF 14A | — | 0001714899-26-000054 | Denali Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 270 | Section 10a, Apellis Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0000950170-25-056966 | Apellis Pharmaceuticals, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 271 | Section 10a, Arcutis Biotherapeutics, Inc. reciprocity | DEF 14A | — | 0001787306-26-000028 | Arcutis Biotherapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 272 | Section 10a, Halozyme Therapeutics, Inc. reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 273 | Section 10a, Axsome Therapeutics, Inc. reciprocity | DEF 14A | — | 0001193125-26-177610 | Axsome Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 274 | Section 10a, Blueprint Medicines Corporation reciprocity | DEF 14A | — | 0001558370-25-005415 | Blueprint Medicines Corporation's most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 275 | Section 10a, Vaxcyte, Inc. reciprocity | DEF 14A | — | 0001193125-26-173672 | Vaxcyte, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 276 | Section 10a, BridgeBio Pharma, Inc. reciprocity | DEF 14A | — | 0001140361-26-016723 | BridgeBio Pharma, Inc. names Roivant Sciences Ltd. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 277 | Section 10a, Intra-Cellular Therapies, Inc. reciprocity | DEF 14A | — | 0001628280-24-018986 | Intra-Cellular Therapies, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 278 | Section 10a, Karuna Therapeutics, Inc. reciprocity | DEF 14A | — | 0000950170-23-014979 | Karuna Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 279 | Section 10a, Cerevel Therapeutics Holdings, Inc. reciprocity | DEF 14A | — | 0000950170-23-015766 | Cerevel Therapeutics Holdings, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
| 280 | Section 10a, ImmunoGen, Inc. reciprocity | DEF 14A | — | 0001558370-23-006874 | ImmunoGen, Inc.'s most recent proxy was read; its disclosed peer group does not include Roivant Sciences Ltd.. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Roivant Sciences Ltd. Executive Compensation Report
$1,500